LAMICTAL CD Drug Patent Profile

When do Lamictal Cd patents expire, and what generic alternatives are available?

Lamictal Cd is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in LAMICTAL CD is lamotrigine. There are thirty-two drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the lamotrigine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lamictal Cd

A generic version of LAMICTAL CD was approved as lamotrigine by DR REDDYS LABS LTD on January 22^nd, 2009.

Summary for LAMICTAL CD

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	95
Patent Applications:	4,481
DailyMed Link:	LAMICTAL CD at DailyMed

Recent Clinical Trials for LAMICTAL CD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BioPharma Services Inc.	PHASE1
Desitin Arzneimittel GmbH	PHASE1
Dr Cipto Mangunkusumo General Hospital	Phase 4

See all LAMICTAL CD clinical trials

Pharmacology for LAMICTAL CD

Drug Class	Anti-epileptic Agent Mood Stabilizer
Mechanism of Action	Dihydrofolate Reductase Inhibitors Organic Cation Transporter 2 Inhibitors
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

US Patents and Regulatory Information for LAMICTAL CD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	LAMICTAL CD	lamotrigine	TABLET, FOR SUSPENSION;ORAL	020764-004	Sep 8, 2000	AB	RX	Yes	No
Glaxosmithkline Llc	LAMICTAL CD	lamotrigine	TABLET, FOR SUSPENSION;ORAL	020764-003	Aug 24, 1998		DISCN	No	No
Glaxosmithkline Llc	LAMICTAL CD	lamotrigine	TABLET, FOR SUSPENSION;ORAL	020764-001	Aug 24, 1998	AB	RX	Yes	No

International Patents for LAMICTAL CD

See the table below for patents covering LAMICTAL CD around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	9202962	1,2,4-DERIVADOS DE TRIAZINA, PROCESO PARA PREPARAR DICHOS COMPUESTOS Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
German Democratic Republic	151309	VERFAHREN ZUR HERSTELLUNG VON SUBSTITUIERTEN AMINOTRIAZINEN
Spain	491998

Supplementary Protection Certificates for LAMICTAL CD

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0021121	94C0016	Belgium		94C0016, 19941006

LAMICTAL CD: Market dynamics and financial trajectory

Last updated: April 24, 2026

What is LAMICTAL CD in commercial terms?

Lamictal CD is the extended-release (CD) formulation of lamotrigine marketed by GSK (brand owner for Lamictal). The product sits in the antiepileptic drug (AED) category and competes primarily against other lamotrigine formulations and broader AED regimens used for epilepsy and mood indications (where clinically applicable).

Because this request is specifically about “LAMICTAL CD” rather than the broader Lamictal franchise, the analysis targets the extended-release product line rather than all immediate-release lamotrigine presentations.

How do market dynamics shape LAMICTAL CD demand?

Demand for Lamictal CD is driven by three forces: indication mix, payer access, and competitive substitution across lamotrigine formulations.

Indication and channel mix

Lamotrigine brands in the market typically monetize across:

• Epilepsy: long-term maintenance therapy with clinician-driven switching only when clinically justified.
• Bipolar disorder: where lamotrigine is used, payer authorization and formulary placement matter.

In practice, extended-release versions can gain share where prescribers and formularies value dosing convenience and adherence.

Formulary and payer access is the primary near-term determinant

In branded AEDs, the dominant commercial dynamic is payer behavior:

• Formulary tiering: preferred tiers reduce friction; non-preferred placement increases prior authorization and co-pay barriers.
• Step edits: payers frequently require trial of generics or alternative AEDs before covering brand.
• Generic substitution pressure: lamotrigine generics are widely available; branded extended-release usually loses incremental demand unless a formulation-specific advantage maintains access.

Competitive substitution pressure is structural

Lamictal CD faces substitution on two axes:

1. Generic lamotrigine (immediate-release and extended-release) where available in the same dosing pattern.
2. Other AED classes (levetiracetam, lacosamide, valproate, etc.) depending on payer preferred lists and clinical guidelines.

This creates a market where branded share depends less on new prescriber starts and more on retention of existing patients and defense of formulary position.

What does the financial trajectory look like post-generic pressure?

Lamictal branded revenues generally follow a pattern typical of mature neurological brands facing generic entry:

• Early-life growth from new starts and incremental indication uptake.
• Plateau as generics expand market availability.
• Decline in branded unit economics as share shifts to generics and payer restrictions tighten.
• Stabilization if the brand maintains a meaningful “no substitution” segment or if extended-release dosing retains clinician preference.

Expected directionality for LAMICTAL CD

For a specific branded extended-release segment (“CD”):

• Unit growth is constrained by broad generic availability of lamotrigine products.
• Revenue erosion is driven by both lower net price (rebates/discounting under payer pressure) and lower volume (switching to generics).
• Earnings impact is amplified because branded gross-to-net compression rises as payers demand larger discounts to maintain access.

This trajectory is consistent with the commercialization reality of long-cycle epilepsy drugs in the era of widespread generic substitution.

Financial sensitivity points

For Lamictal CD specifically, the revenue line is most sensitive to:

• Formulary wins/losses for extended-release lamotrigine (not just lamotrigine broadly).
• Net price changes from contract renewals and rebate adjustments.
• Lifecycle management: the ability (or inability) to maintain differentiation versus generic extended-release competitors.

What market indicators should investors track for LAMICTAL CD?

The most decision-useful indicators for this product segment fall into five buckets.

1) Prescriber and payer access signals

• Formulary status in top commercial plans
• Prior authorization rate and criteria changes
• Step-edit updates for branded lamotrigine ER

2) Relative share by formulation

• Share shifts between immediate-release vs extended-release within lamotrigine
• Share between brand ER and generic ER

3) Net price and rebate pressure

• Contract re-pricings at formulary renewal cycles
• Gross-to-net compression trends

4) Competitive launches and withdrawals

• Launches of generic extended-release versions
• Any legal or supply events that temporarily change availability

5) Indication retention

• Patient persistence on ER dosing
• Switching behavior driven by tolerance, seizure control, and adherence

How does the regulatory and IP landscape affect the brand trajectory?

LAMICTAL CD’s branded economics are shaped by the IP runway of lamotrigine formulations and by the timing of generic market entries for equivalent dosing forms. In the mature stage of lamotrigine, branded products typically operate with:

• Limited ability to prevent substitution for composition-of-matter once generics are established.
• Reliance on formulation-specific protection only where applicable and only for the remaining term.

This makes the commercial trajectory more a function of payers and contracting than of new exclusivity gains.

What is the likely revenue path for LAMICTAL CD within the Lamictal portfolio?

Within Lamictal’s commercial footprint, extended-release segments usually:

• Contribute material revenue while differentiated access lasts.
• Then decline in share once payer coverage widens for equivalent generics.

As a result, the financial path for LAMICTAL CD tends to be:

• Decline after generic saturation (net sales and volume both soften)
• Stabilization only if payer coverage continues to favor the brand ER segment
• Renewed pressure when new generic ER entrants expand substitution options or when rebates required to maintain access increase

Where can LAMICTAL CD still win in market share?

Even under heavy generic pressure, branded extended-release products can sustain demand through:

• Existing patient retention where dosing convenience and tolerability matter.
• Clinician preference for consistent pharmacokinetic profiles.
• Payer access arrangements that treat brand ER as the “covered” option for a subset of patients (for example, those with prior intolerance to substitutes).

However, the ceiling for incremental share is low once generic ER coverage becomes standard across major formularies.

What business actions follow from this market structure?

The market mechanics imply a small set of concrete strategic priorities for brand defense and forecasting:

• Tight payer contracting strategy: focus on net price resilience and rebate affordability tied to formulary placement.
• Segment-specific retention programs: protect persistence among patients who respond to ER lamotrigine.
• Competitive intelligence on substitution: monitor when generic ER supply and coverage widen, because that is when volume usually shifts fastest.
• Forecast modeling by channel: separate commercial, managed care, and other channels because switching behavior differs by payer mix.

Key Takeaways

• LAMICTAL CD demand is primarily determined by payer access and substitution dynamics rather than new growth from prescriber expansion.
• The extended-release brand segment faces persistent generic pressure that compresses net price and erodes volume over time.
• Financial trajectory is expected to show post-generic decline with limited stabilization, driven by formulary wins, rebate levels, and patient retention.
• The most decision-relevant monitoring targets are formulary status, net price/gross-to-net, ER versus IR share shifts, and step-edit/prior authorization changes.

FAQs

1. Is LAMICTAL CD differentiated versus generic lamotrigine in commercial practice?
   Differentiation is mainly formulation-level and access-level. When payers cover generic ER broadly, the incremental advantage narrows to retention and contract-driven exceptions.

2. What most directly affects net sales for LAMICTAL CD?
   Gross-to-net compression and volume shift due to formulary substitution are typically the largest drivers.

3. Does the seizure indication drive durable demand for ER lamotrigine brands?
   Epilepsy maintenance supports persistence, but substitution still occurs when payers incentivize switching or when coverage constraints tighten.

4. Which market changes usually trigger faster volume declines for branded ER products?
   Broader generic ER coverage, increased step edits, and reductions in brand tier placement tend to accelerate switching.

5. How should forecasts be modeled for LAMICTAL CD?
   Use payer-by-payer assumptions on formulary status and substitution rates, then layer net price trajectory tied to rebate pressure and contract renewal timing.

Sources (APA)
[1] GSK. Lamictal (lamotrigine) product information and labeling. (Accessed via company and regulatory repositories).
[2] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Lamotrigine extended-release and formulation-specific entries).
[3] FDA. Drug approvals and labeling database for lamotrigine formulations (for product history and references).